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Abstract
Background: Waterpipe tobacco smoking has increased among youth across the globe including in the US, and it
continues as a common and traditional form of smoking tobacco in Pakistan. A range of behavioral and
pharmacological therapies are available to support people in quitting cigarette smoking; however, little evidence exists
for the efficacy of these therapies in achieving abstinence among waterpipe tobacco smokers. The objective of this
study is to assess the efficacy of varenicline when added to behavioral support for waterpipe tobacco smoking cessation,
by measuring biochemically validated continuous abstinence in waterpipe tobacco smokers.
Methods/design: This is a two-arm, double-blind, placebo-controlled randomized trial conducted in four districts in
Punjab, Pakistan. Study participants include adults using a waterpipe (with or without concomitant cigarette, bidi or
other forms of tobacco smoking) on a daily basis for at least 6 months and who are willing to quit. We will individually
randomize 510 participants to one of the two arms of the trial. Participants in the intervention arm will receive
varenicline and behavioral support and those in the control arm will receive placebo and behavioral support. The
primary outcome will be continuous abstinence for at least 6 months (week 25) which is biochemically verified by a
carbon monoxide level of <10 ppm. Secondary outcomes will include biochemically verified 7-day point abstinence at
5, 12 and 25 weeks and any lapses and relapses between the different assessment points. Tertiary outcomes will
include assessment of withdrawal symptoms using the Mood and Physical Symptoms Scale (MPSS), smoking
dependency using the Lebanon Waterpipe Dependency Scale (LWDS-11) and monitoring adverse outcomes.
Discussion: This is an efficacy trial and would require a subsequent effectiveness trial for a definitive evaluation of the
intervention.
Trial registration: ISRCTN, ISRCTN94103375. Registered on 1 December 2015.
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Background
Waterpipe tobacco smoking, also known as hookah, Shisha
or narghile, is a growing public health concern worldwide.
In waterpipe tobacco smoking, tobacco is heated by burning
charcoal in a stemmed, water-containing apparatus. Users
inhale a mixture of tobacco and charcoal smoke by breath-
ing in on a hose that is attached to the apparatus. One
waterpipe session can last between several minutes to several
hours [1]. The activity has been practiced for centuries and,
while popularity has markedly increased worldwide, it re-
mains embedded within south Asian culture, particularly in
Pakistan. According to the latest Global Adult Tobacco Sur-
vey (GATS, 2014) conducted in Pakistan, 22.2% of men,
2.1% of women and 12.4% of the overall adult population
currently smoke tobacco (15.6 million adults currently
smoke tobacco). The same survey states that 4.7% of men,
1.1% of women and 3.0% of the overall adult population cur-
rently use a waterpipe (3.7 million adults). Furthermore, the
GATS, 2014 states that about one in four smokers made an
attempt to quit in the past 12 months. Despite the widely
held belief that waterpipe tobacco smoking is safer than
cigarette smoking [2], research has shown the contrary. The
tobacco mixture contains significant levels of nicotine,
known for its addictive properties, as well as tobacco-
specific nitrosamines, volatile aldehydes, heavy metals and
“tar,” which cause respiratory diseases and cancer [3, 4].
Tobacco-like adverse health effects from waterpipe tobacco
smoking are, therefore, expected and well-documented in a
recent meta-analysis, which revealed a positive association
between waterpipe tobacco smoking and lung (odds ratio
(OR) 4.6, 95% CI 2.6–8.0) and esophageal (OR 3.6, 95% CI
1.4–9.4) cancers [5]. As with cigarettes, nicotine depend-
ence is a key feature of regular waterpipe tobacco smokers
who exhibit cravings, withdrawal symptoms and other
nicotine-modulated behaviors [6, 7].
The effectiveness of smoking-cessation strategies includ-
ing behavioral support and pharmacotherapies, such as var-
enicline, has been well-established among cigarette smokers
[8, 9]. Varenicline has also shown to be more effective and
cost-effective than nicotine replacement therapy [10] and
bupropion [11], respectively. In a previous study [12] behav-
ioral support was found to be effective among hookah
smokers (relative risk (RR) 2.2; 95% CI 1.3–3.8) but to a
lesser extent than among cigarette smokers (RR 5.8; 95% CI
4.0–8.5). This study was a subgroup analysis of a large clus-
ter randomized controlled trial (RCT) (Action to Stop
Smoking In Suspected Tuberculosis) in Pakistan, which
found 41.0% smoking abstinence in the behavioral support
group compared to 8.5% in the control group [13]. Com-
bining varenicline with behavioral support has further po-
tential in increasing cessation success [14]. However, the
efficacy of varenicline (either alone or in combination with
other therapies) in waterpipe tobacco smoking cessation is
currently unknown. The two RCTs to date assessing the
effectiveness of smoking cessation strategies in waterpipe
tobacco smokers did not evaluate varenicline [12, 15].
Moreover, these trials have either shown little or modest
success in getting waterpipe tobacco smokers to quit as
compared to cigarette smokers [12, 15]. This calls for fur-
ther therapies, such as varenicline, to be evaluated in this
population. This study will be the first to explore the effi-
cacy of varenicline in waterpipe tobacco smoking cessation.
Given the increased use of the waterpipe use across all con-
tinents and the paucity of evidence on interventions for its
cessation, this study is critically important for public health
and could provide a scientific breakthrough in this area.
The items in this protocol comply with the recommended
SPIRIT checklist (Additional file 1).
Methods/design
Aims and objectives
Our key aim is to assess whether varenicline coadminis-
tered with behavioral support is more efficacious in
achieving 6 months’ continuous abstinence from all
forms of tobacco smoking among waterpipe tobacco
smokers than a combination of placebo and behavioral
support. Therefore, the primary objective of the trial is
to assess the efficacy of varenicline when added to be-
havioral support for smoking cessation, by measuring
biochemically validated continuous abstinence at week
25 in waterpipe tobacco smokers. The secondary objec-
tives are to: (1) assess the efficacy of varenicline when
given with behavioral support in achieving point abstin-
ence at week 5, week 12 and week 25, (2) compare the
efficacy of varenicline when given with behavioral sup-
port in achieving point and continuous abstinences be-
tween exclusive waterpipe tobacco smokers and those
who combine it with other forms of smoking tobacco,
(3) assess the proportion of early and late lapses, and
their ability to predict abstinent failures and (4) assess
the proportion of early and late relapses and determine
their predictors. In addition, we will first translate and
then assess the psychometric properties of the Mood
and Physical Symptoms Scale (MPSS) and the Lebanon
Waterpipe Dependency Scale (LWDS-11) in the target
population.
Design
This is a two-arm, double-blind, placebo-controlled, ran-
domized trial. Participants randomized to treatment
(arm 1) will receive varenicline while those randomized
to the control arm (arm 2) will receive placebo. In
addition, behavioral support will be provided to
participants in both arms.
Settings
The study is being conducted in four districts (Chakwal,
Khushab, MandiBahauddin, and Rawalpindi) of Punjab,
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Pakistan. Based in district hospitals in three districts and
a teaching hospital in one district (Rawalpindi), the study
will recruit participants from a large catchment popula-
tion in both urban and rural settings.
Study participants
We will recruit 510 adults who smoke a waterpipe on a
daily basis for at least 6 months, with or without con-
comitant cigarette, bidi or other tobacco smoking and
who wish to quit smoking. We define daily waterpipe
tobacco smoking if a person smokes on more than
25 days in a month. We will exclude those who (1) have
used any pharmacotherapy for tobacco dependence
(including nicotine replacement therapy and electronic
cigarettes) in the last 30 days, (2) are pregnant, lactating
or planning to become pregnant, (3) have a medical con-
dition requiring hospitalization, (4) have previously used
varenicline and had an allergic reaction, (5) have a his-
tory of heart disease, including unstable angina, un-
treated cardiac arrhythmia, myocardial infarction, or
have undergone a cardiac procedure (in the last
3 months), (6) have uncontrolled hypertension or a his-
tory of stroke, (7) have a history of chronic kidney
disease, (8) have a history of epilepsy, (9) have suicidal
ideation or a history of self-harm, (10) have a history of
schizophrenia, psychosis or bipolar disorder, (11) have
current moderate or severe depression, (12) currently
use smokeless tobacco and (13) actively use substances
(including alcohol misuse) other than tobacco.
The following methods will be used to identify and
recruit potential participants:
1. Recruiting hospital patients: we will provide half-day
training to all health care staff in each hospital to
identify potential trial participants among adult
hospital attendees and refer them to a research
assistant based in a respective hospital for eligibility
assessment
2. Recruiting patients’ relatives/attendants: we will put
up posters and make leaflets available in the
reception hall, outpatient departments, hospital
wards and other relevant departments with a brief
explanation about the study and inviting
participants. These will be targeted at patients as
well as their attendants. Interested people will be
asked to contact a respective research assistant
3. Recruiting members of public: we will also recruit
eligible and consenting individuals among catchment
populations of the participating hospitals. We will
advertise our trial and invite people to participate
through local newspapers, local cable TV and/or
using community networks. Interested people will be
also identified through local connections and/or
previously enrolled participants in the trial and put
in contact with the research assistant. Individuals
recruited via community networks will be offered
trial enrollment in the community in case they are
not able to visit the respective hospital site
Once identified and referred to our resident research
assistant, all potential participants will be assessed for
eligibility. Research assistants will be trained to go
through the inclusion and exclusion criteria and make a
final eligibility assessment. A screening register will be
kept at each site, which will have potential participants’
“screening” number, responses to questions asked to as-
sess eligibility and the outcome of their eligibility assess-
ment. Those found to be eligible will be given verbal and
written information about the trial and 24 h to consider
participation. Potential participants will be given an op-
portunity to clarify anything that they do not understand
and ask related questions. It will also be explained that
they are free to leave the study at any point without any
consequences on their routine and entitled medical
treatment. Participants will not receive any financial in-
centives to participate in the trial except to cover their
travel expenses. Written consent will be obtained by the
research assistant from those interested by going
through a checklist on the Consent Form and obtaining
an ink signature or a thumb impression (thumb impres-
sion is officially acceptable in Pakistan for those who
cannot write). The outcome on the Consent Form will
also be recorded on the eligibility register. All eligible
and consenting participants will be formally enrolled in
the trial and a minimum set of information (sex, con-
comitant smoking other than waterpipe) will be ob-
tained, necessary for randomization. Where applicable,
reasons for not meeting the eligibility criteria or declin-
ing to participate will be recorded on the screening
register.
Treatment can be withdrawn at any time after
randomization and allocation if significant intolerance to
the study treatment is suspected. Other reasons for with-
drawing from study treatment are: (1) the participant
makes a voluntary decision to withdraw from the study,
(2) the participant has a serious clinical adverse event,
develops a new medical condition or suffers from wors-
ening of any existing illness, which indicates that con-
tinuing in the study will not be in their best interest.
Study treatment will also be withdrawn if the participant
develops a life-threatening or severely disabling medical
condition, or requires hospitalization and (3) female par-
ticipants who become pregnant or intend to become
pregnant. If a participant is withdrawn from the study
due to treatment intolerance or for any of the above rea-
sons, their follow-up assessments and data collection
will continue as per protocol. If the treatment is discon-
tinued due to drug intolerance or any serious clinical
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adverse event, the participant will be followed up until
the intolerance/event subsides and there is a return to
an acceptable clinical status, ascertained by a physician.
Randomization and allocation
Those who consent will be randomly assigned to one of
the two treatment conditions by using a computer-
generated allocation sequence designed at the University
of York. The system, created in software R v3.2.2, will
generate a permuted block randomization list for each
site with stratification factors including gender and
concomitant smoking. Based on this random sequence,
the system will allocate each newly recruited participant
either to varenicline or to placebo treatment. For treat-
ment allocation, the research assistant will make a phone
call to the trial manager based at the central research of-
fice in Islamabad. On providing the basic information on
recruiting district, gender, and concomitant smoking,
the trial manager will generate a trial ID by running a
prespecified code (for each random block) in the R file.
At this point, both the trial manager and the research
assistant will be unaware of the treatment condition as-
sociated with each trial ID. The trial ID will correspond
to that on the medication packs already made available
at each participating hospital. Under no circumstances
will an enrolled participant be dispensed a medication
pack other than the one assigned through the
randomization system. To ensure double-blinding, we
will use identical medication packs for both placebo and
varenicline, labeled only with a unique trial ID. The in-
vestigators, research assistants and participants will be
blinded to the allocation until the trial database is locked
at the end of the study.
Interventions
Once enrolled, participants in the trial will be random-
ized to receive behavioral support either with varenicline
or with placebo.
Behavioral support
Behavioral support will be offered to all waterpipe
tobacco smokers as part of routine care. Hence, all trial
participants, irrespective of their treatment condition,
will receive behavioral support intervention using an
educational flipbook. This will consist of two structured
sessions. A 30-min session at the first visit will aim to
encouraging waterpipe tobacco smokers to see them-
selves as nonusers and to set a plan for a quit day 1 week
later. This is then followed by a 10-min session, coincid-
ing with their quit day, to review progress. Further en-
couragement and support will be offered at subsequent
visits in week 5.
Varenicline
Participants allocated to the varenicline and behavioral
support arm will receive their first week’s supply on the
day of trial enrollment. The treatment, in the form of
0.5-mg tablets, will be dosed at 0.5 mg once daily on
days 1–3 and 0.5 mg twice daily on days 4–7.
Participants will be expected to return at the end of
week 1, coinciding with their quit day, at which point
they will be dispensed another pack of medication for
11 weeks, with the pill in the form of 1-mg tablets to be
taken twice daily for the rest of the treatment duration.
Adherence will be monitored at each visit by using a 7-
day timeline follow-back and by looking at the tablets
left in the bottle. A 7-day timeline follow-back will con-
sist of a set of questions administered at weeks 1, 5 and
12 asking participants if they have taken the prescribed
treatment in the previous week by recalling each day of
the week. Adherence will be considered “complete” if
the participant adheres throughout 12 weeks; and “par-
tial” if adherence is either irregular or not for the entire
period. Participants will be asked to record the nature,
timing and duration of any adverse events (AEs) with
clear guidance on when to stop the medication and
when, and how, to report back to the named clinician in
the participating hospital. These clinicians would have
received the basic training required in this regard.
Placebo
By virtue of being a double-blind trial, participants allo-
cated to the placebo and behavioral support arm will be
dispensed placebo in exactly the same manner as de-
scribed above for varenicline, i.e., a pack of 0.5-mg tab-
lets in the first week and a 1-mg pack for the following
11 weeks.
Pfizer is responsible for ensuring that the quality and
quantity of the study treatment is adequate for the trial.
All treatment packs were shipped to the central research
office in Islamabad and the trial manager is responsible
for storing these at room temperature. An independent
researcher was employed to give the treatment packs
their allocation IDs. A list of these trial IDs will be for-
warded to the trial statistician who will feed this into the
computer program that will generate a random alloca-
tion sequence. The treatment packs will then be given
out to each hospital where these will be stored in a
locked cupboard at room temperature within the
hospital pharmacy. Although medication packs will not
disclose the treatment condition, their labels will contain
the following information: (1) LOT number given by
Pfizer, (2) unique trial ID given by an independent re-
searcher, (3) principle investigator’s details, (4) sponsor’s
details, (5) hospital address, (6) expiry date, (7) patient’s
name and (8) directions for use. Each pack will also
clearly say “For use in Hookah Trial only.” A treatment
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supply register will be kept both at the hospital as well
as at the central research office. All left-over treatment
packs will be returned from the participating hospital
sites to the central research office and will be disposed
off after completion of the trial follow-ups.
Primary outcome
As per Russell’s Standard [16], the primary outcome will
be self-reported continuous abstinence for at least
6 months (no smoking allowed in the 7 days prior to each
of the three assessments) which is biochemically verified
by a carbon monoxide (CO) level of <10 ppm measured
by Micro CO (Micro Medical Ltd., Rochester, United
Kingdom) at week 5, week 12 and week 25. When a
participant self-reports abstinence with an elevated CO
level of >10 ppm on any of the three assessments, we will
use urinary kits for checking cotinine levels in such cases.
Depending on the cotinine level findings the participant
will be categorized as a smoker or not.
Secondary outcomes
Based on the combination of self-report and CO levels,
these will include:
1. Point abstinence, defined as a self-report of not
smoking in the previous 7 days and verified by a CO
level of <10 ppm, at week 5, week 12 and week 25
2. Early lapse, defined by a self-report of smoking (even
once) after the quit date but having point abstinence
at week 5
3. Late lapse, defined by a self-report of smoking (even
once) between week 5 and week 12 but showing
point abstinence at week 5 and week 12
4. Early relapse, defined by point abstinence at week 5
but a smoking status in later assessments
5. Late relapse, defined by point abstinence at week 5
and week 12 but a smoking status at week 25
6. Differences in the point and continuous abstinences,
lapses and relapses between exclusive waterpipe
smokers and those who combine it with other forms
of smoking tobacco
We will also translate the MPSS [17] for use in a Pakistani
population. Once translated, the scale will be administered
at baseline and week 25. The scale assesses withdrawal
symptoms including anxiety, depression, irritability, restless-
ness, hunger, concentration and sleep. It also assesses the
frequency and strength of urges to smoke. As above, we will
also translate the LWDS-11, a tobacco-dependence measure
[7], to be administered at baseline and week 25. The scale
consists of 11 items and four subscales, the first representing
nicotine dependence, the second negative reinforcement,
the third psychological craving and the fourth positive
reinforcement.
Data collection and management (Fig. 1)
All participants will undergo a baseline assessment in-
cluding demographic variables (e.g., age, sex, ethnicity,
socioeconomic status), past and present smoking (all
forms), motivation to quit, withdrawal symptoms (MPSS)
and dependency assessments (LWDS-11). Information on
waterpipe use will also be collected which will include the
quantity, duration and frequency of waterpipe tobacco
smoked at the baseline. We will also enquire about their
knowledge of health risks associated with waterpipe
tobacco smoking, attitudes towards waterpipe tobacco
smoking, and intention to quit. The use of concomitant
medications will also be collected at baseline. Although
social support is not directly assessed, whether smoking is
permitted inside the home is assessed. Further assess-
ments at weeks 5, 12 and 25 will include current smoking,
any changes in smoking patterns, medication-related AEs
and CO breath tests. MPSS, LWDS-11, Strength of Urges
to Smoke (SUTS) and cotinine urine tests will be carried
out at week 25 (Fig. 2). To pay for their travel and subsist-
ence expenses, participants will receive 200 Pakistani Ru-
pees (approximately US$2) at the last follow-up. Those
failing to attend will be reminded and asked to at least
send their smoking status via text (mobile phone coverage
is high in Pakistan). Where possible, a home visit will be
arranged to perform CO measurements. In our previous
experience of conducting smoking-cessation trials in
Pakistan, such strategies have been successful in keeping
attrition rates below 10% [13]. Data will still be collected
and maintained on those who either discontinue or devi-
ate from treatment protocols to assess fidelity to the treat-
ment. Data will be initially collected in the form of paper-
based questionnaires. Containing no participant-
identifiable information, these will be kept in a locked
cupboard separate from the Consent Forms at the partici-
pating hospital. Every week, these will be photocopied and
sent over to the central research office through a secure
courier service. Once received, data will be entered in a
secure trial database managed by the University of York,
created using Qualtrics software (Qualtrics, Provo, UT,
USA). Paper copies will also be kept secure in a locked
cupboard.
Adverse events
There will be a vigilant surveillance system in place for
adverse events (AEs) occurring during the course of the
trial with particular emphasis on identifying, recording,
reporting and managing serious suspected drug reac-
tions. We will use standard definitions to distinguish be-
tween an adverse event (AE), a serious adverse event
(SAE) and a serious suspected adverse drug reaction
(SSARD).
In the event of any AE reported by the participant,
their attendant or health care staff, the research assistant
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will complete an AE Form, which will include any avail-
able medical diagnosis. For reporting SAEs, a form will
be provided by Pfizer known as a Pfizer-provided
Investigator-initiated Research Serious Adverse Event
Form. The Reportable Event Fax Cover Sheet provided
by Pfizer will also be included with each SAE submitted.
The research assistant will photocopy and complete this
form, send it in the post to the central research office
and call the trial manager on the same day providing a
verbal report of the event. The research assistant will be
trained to differentiate between AEs and SAEs. However,
the trial manager, who is medically qualified, will ensure
that the event is classified appropriately after receiving
the verbal report. The trial manager will also code the
event using the Medical Dictionary for Regulatory Activ-
ities (MedDRA) [18] and cascade the information as
follows.
All AEs must be reported to the principal investigator
(Pakistan) within 3 days of detection. AE data will be
collated and reported to the trial sponsors and National
Bioethics Committee at 6-monthly intervals. These must
also be reported to the Study Operational Committee
and the Independent Trial Steering Committee at their
regular meeting. All AEs that have the potential to de-
velop into SAEs will be followed to resolution or
stabilization and reported as SAEs if they become ser-
ious. All SAEs must be reported to the principal investi-
gator and Pfizer within 24 h of detection and should also
Fig. 1 CONSORT Flow Diagram
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be reported to the trial sponsors and the National Bioeth-
ics Committee within three working days. All SSARDs
should be reported to the sponsors and the committee
within 24 h of the event. All serious events must also be
reported to all study investigators and the chair of the In-
dependent Trial Steering Committee (within 3 days for
SAEs and within 24 h for SSARDs). If the trial manager
requires more detail in relation to any SAEs or SSARDs
then they may request the trial statistician to unblind the
treatment condition. The chief investigator will have the
overall responsibility to ensure that all AEs are reported
according to the above protocol.
In addition to assessing seriousness, the trial manager,
who is medically qualified, will assess all AE for causality,
severity and expectedness. This will be done in consult-
ation with the principal investigator and the event will be
classified as follows:
Unrelated: when the event is considered not related to
the study treatment
Possibly: when an association of the event with the
study treatment cannot be ruled out
Probably: when temporal association and an absence of
any other explanation suggest that the event could be
related to the study treatment
Definitely: based either on known side effects of the
study treatment or on challenge testing, a suggestion that
the study treatment is the most likely cause of the event
All AEs/SAEs that fall under the possible, probable or
definitive category will be classified as adverse reactions
or SSADRs.
The trial manager can make the following assessment
based on severity, which should not be confused with
seriousness (a statutory definition) differentiating between
AEs and SAEs:
Mild: these events cause minimal discomfort, are easily
tolerated and do not interfere with routine life activities
Moderate: these events cause moderate discomfort and
do interfere with routine life activities
Severe: these events cause much discomfort and lead
participants to stop their routine life activities
If the event is judged to be an adverse reaction, serious
or otherwise, this must be judged on expectedness based
on what is already known on the safety profile of the drug
under study. Each participating hospital site will have a
named medical practitioner who will be responsible for
dealing with any AE that requires medical attention. All
Fig. 2 Data collection schedule
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medical expenses resulting from such events will be cov-
ered by the trial budget. This will not include any elective
procedures, operations or admissions planned prior to
participating in the trial. In addition to collecting detailed
clinical information on the AE Form, other relevant
medical information will be collected from hospital. These
events will be followed up till resolution or returning to a
stable medical state. We will not expect any events that
occur after the completion of follow-up to be relevant to
the trial and, therefore, no active surveillance will continue
beyond trial completion. Nevertheless, any event reported
to the trial manger will be recorded and kept in the
records along with other trial data.
Sample size
The primary outcome of the study is continuous
abstinence for at least 6 months between week 5 and
week 25. Our previous data from a clustered randomized
trial in 33 centers in Pakistan [13] with 1955 participants
gave an estimate of 37% continuous abstinence at
25 weeks for the behavioral support arm of the trial. A
difference of an additional 13 percentage points in the
varenicline group is the minimum clinically important
difference that we are interested in detecting; this is the
median difference reported by the trials which looked at
the effectiveness of varenicline and were included in the
systematic review by Cahill et al. [8]. In order to detect
an absolute difference of 13% in the varenicline plus be-
havioral support versus the placebo plus behavioral sup-
port group, with 80% power and 5% significance, 228
patients would be required per arm. Allowing for a 10%
dropout, a total of 508 patients will, therefore, need to
be recruited into the study.
Statistical analysis
A Consolidated Standards of Reporting Trials (CONSORT)
diagram (Fig. 1) shows the flow of participants through the
trial. Baseline data including demographic variables will be
summarized descriptively by trial arm but no formal statis-
tical comparisons will be undertaken. Continuous measures
will be reported as means and standard deviations while cat-
egorical data will be reported as counts and percentages.
The main analysis will use log-binomial regression for
the primary outcome to estimate any difference in risks
between the two arms of the study adjusting for baseline
data. We will also investigate any potential clustering at
the centre level and family/friends’ level and adjust for it
in the regression model. A similar approach will be used
for the binary secondary outcomes, namely point abstin-
ence at weeks 5, 12 and 25, lapse between weeks 5 and
12, weeks 12 and 25 and weeks 5 and 25. A subgroup
analysis of point and continuous abstinence will com-
pare participants with or without concomitant smoking;
this analysis will be conducted by exploring whether
there is an interaction between the treatment arm and
whether someone exclusively smokes a waterpipe or
combines it with other forms of tobacco consumption.
The MPSS items will be analyzed individually, sum-
mated to give an overall score and scored in three blocks
as suggested by West et al. [17]. Similar approaches will
be used for the LWDS-11 [7] and SUTS [19] scales. Ap-
propriate regression analysis will be used for each out-
come, linear for the summated scores if the assumptions
are met, otherwise appropriate measures will be taken,
and ordered logistic regression used for the Likert-scale
individual items. Analysis of AEs and SAEs will explore
whether these differ by treatment arm using chi-square
tests. In case of missing data, multiple imputations and
appropriate sensitivity analyses will be conducted. As it
is likely that more than one variable will have missing
data we will use multiple imputations using chained
equations (MICE). A minimum of 10 imputations will
be performed; however, the final number of imputations
will depend on the missing data. We will report the deci-
sions that we make with regard to the number of impu-
tations and the variables we use in the imputations. We
will also conduct a sensitivity analysis to explore the im-
plications of the missing-at-random assumption [20, 21].
A significance level of 0.05 will be used for the primary
analysis whereas this will be 0.1 for the secondary
analyses.
Discussion
The trial will be conducted to protect the human rights
and dignity of the participant as reflected in the 1996
version of the Helsinki Declaration. Participants will not
receive any financial inducement to participate in the
trial. In order to protect the trial participants, the follow-
ing provisions will be made/upheld: the trial has been
designed to minimize the burden on participants and
any foreseeable risk in relation to the intervention in-
volved; the explicit wishes of the participant will be
respected including the right to withdraw from the trial
at any time; the interest of the participant will prevail
over those of science and society; provision will be made
for indemnity by the investigator and sponsor. We will
deal with key ethical issues in our research as follows:
 We will obtain written consent from all those who
are eligible and, after having received trial
information (in the local language) and sufficient
time (24 h) to consider, are willing to participate.
Those unable to sign will be requested to provide a
thumb impression on the consent from, a common
and acceptable alternative to a signature in Pakistan
 In line with the Data Protection Act and the
Research Governance Framework, all data collected
will be confidential, being identified with the unique
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enrollment number only assigned at the beginning
of the trial. The research team will maintain the key
linking these numbers with the participants’ contact
details. Access to the master key register will be
limited to researchers via a password-protected
database
 All investigators and collaborators at each research
site will be required to submit an individual
statement declaring any conflicts of interest on a
yearly basis reviewed by the Independent Trial
Steering Committee
 Access to the participants’ personal details will be
restricted to the necessary members of the research
team only. Monitors and auditors may also need to
access the data. At the end of the trial, data will be
securely archived by the University of York for a
minimum of 5 years
We have identified following risks associated with this
application and strategies to mitigate these:
 Barriers to obtaining favorable opinion from the Ethics
Committee: this is unlikely as this study does not pose
major risks nor put undue burden on participants
 Delays in obtaining approval from the Ministry of
Health in Punjab, Pakistan: we have the support of
tobacco leadership in Punjab for this project
 Lack of collaboration between investigators and
hospitals: we have secured expression of interest
from all four hospitals to minimize this risk
 Staffing recruitment and retention issues: we will
ensure that all recruitment paperwork is prepared
and posts are advertised in advance
 Risks associated (accidents and violence) with
traveling in Pakistan including: Foreign and
Commonwealth Office’s (FCO) advice will be
followed while making travel arrangements; we will
carry out a full risk assessment according to the
institutional policy before any travel
 Slow recruitment: our eligibility criteria are fairly
broad and recruitment targets realistic based on the
existing service workload and our experience in
recruiting trial participants; we recruited
approximately 2000 participants in a previous
smoking-cessation trial in Pakistan
 Loss to follow-up higher than expected: in the previous
trial in Pakistan we found less than 10% attrition rate
 Protocol violations: this will be minimized through
pilot work, training, supervision, monitoring and
quality control
 Serious adverse events (SAEs): a policy on managing
SAEs will be developed as part of the protocol
 Errors or inconsistencies in data entry and collation:
data management systems and procedures will be
standardized and relevant training will be provided;
quality controls will be put in place to minimize
errors
Being the first RCT of a pharmacological agent for
cessation of waterpipe tobacco smoking, the potential
impact of this trial is likely to be high as it addresses a
key public health concern. To disseminate study findings
to the relevant audience, the study results will be
published in leading peer-reviewed journals and pre-
sented in international public health/tobacco control
conferences. The abstract will be published on the Uni-
versity of York official website and learning from the
project will be incorporated into health promotion lec-
tures for Master’s students of public health. The
National Tobacco Control Cell will be involved at all
stages of the project. A project report and a policy brief
of the research process and results will be compiled.
Events like No Tobacco Day will be utilized to publicize
our work through leaflets, policy briefs and community
talks.
Additional file
Additional file 1: SPIRIT Checklist. (PDF 79 kb)
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